Cargando…

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

BACKGROUND: Although sorafenib is the global standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC), it does not have reliable predictive or prognostic biomarkers. Circulating cell-free DNA (cfDNA) has shown promise as a biomarker for various cancers. We investigated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Chung Ryul, Kong, Sun-Young, Im, Hyeon-Su, Kim, Hwa Jung, Kim, Min Kyeong, Yoon, Kyong-Ah, Cho, Eun-Hae, Jang, Ja-Hyun, Lee, Junnam, Kang, Jihoon, Park, Sook Ryun, Ryoo, Baek-Yeol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444867/ https://www.ncbi.nlm.nih.gov/pubmed/30935424 http://dx.doi.org/10.1186/s12885-019-5483-x

Ejemplares similares

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib
por: Jung, Dong-Hwan, et al.
Publicado: (2015)

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
por: Son, Myoung Kyun, et al.
Publicado: (2017)

Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers
por: Seo, Seyoung, et al.
Publicado: (2016)

EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
por: Hwangbo, Won, et al.
Publicado: (2013)

Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
por: Yoo, Changhoon, et al.
Publicado: (2019)

Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study
por: Park, Kwonoh, et al.
Publicado: (2017)

Comparing copy-number profiles under multi-copy amplifications and deletions
por: Cordonnier, Garance, et al.
Publicado: (2020)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
por: Kim, Do Young, et al.
Publicado: (2016)

An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients
por: Lee, Ji Yun, et al.
Publicado: (2017)

Three Cases of False-positive Multiplex Ligation-dependent Probe Amplification of BRCA1
por: Kim, Kyoung Bo, et al.
Publicado: (2022)

Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion
por: Yoo, Changhoon, et al.
Publicado: (2021)

Primary Systemic Anaplastic Large Cell Lymphoma in a Single Korean Institution: Clinical Characteristics and Treatment Outcome
por: Park, Sook Ryun, et al.
Publicado: (2006)

Absence of antitumor effects of metformin in sorafenib-treated patients with hepatocellular carcinoma recurrence after hepatic resection and liver transplantation
por: Chung, Yong-Kyu, et al.
Publicado: (2018)

Sorafenib Modulates the LPS- and Aβ-Induced Neuroinflammatory Response in Cells, Wild-Type Mice, and 5xFAD Mice
por: Kim, Jieun, et al.
Publicado: (2021)

Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma
por: Jeong, Hyehyun, et al.
Publicado: (2021)

Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression
por: Ryoo, Baek-Yeol, et al.
Publicado: (2021)

VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer
por: Terme, Magali, et al.
Publicado: (2013)

Inhibition of VEGFA Increases the Sensitivity of Ovarian Cancer Cells to Chemotherapy by Suppressing VEGFA-Mediated Autophagy
por: Li, Xia, et al.
Publicado: (2020)

Machine Learning Approaches for Predicting Bisphosphonate-Related Osteonecrosis in Women with Osteoporosis Using VEGFA Gene Polymorphisms
por: Kim, Jin-Woo, et al.
Publicado: (2021)

Amplification of the UQCRFS1 Gene in Gastric Cancers
por: Jun, Kyong Hwa, et al.
Publicado: (2012)

Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
por: Park, Sook Ryun, et al.
Publicado: (2016)

Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC
por: Zito Marino, Federica, et al.
Publicado: (2020)

Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma
por: Kim, Bo Hyun, et al.
Publicado: (2019)

Sorafenib Induces Delayed-Onset Cutaneous Hypersensitivity: A Case Series
por: Sohn, Kyoung-hee, et al.
Publicado: (2015)

RNA-Sequencing data supports the existence of novel VEGFA splicing events but not of VEGFA(xxx)b isoforms
por: Bridgett, Stephen, et al.
Publicado: (2017)

Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification
por: Moreira, Raphael Brandão, et al.
Publicado: (2015)

Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy
por: Jo, Yunhui, et al.
Publicado: (2018)

A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer
por: Ryu, Min‐Hee, et al.
Publicado: (2017)

Impact of whole genome amplification on analysis of copy number variants
por: Pugh, T. J., et al.
Publicado: (2008)

Amplification ratio control system for copy number variation genotyping
por: Guthrie, Philip A. I., et al.
Publicado: (2011)

Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients
por: Shim, Hyoeun, et al.
Publicado: (2022)

Vegfa Protects the Glomerular Microvasculature in Diabetes
por: Sivaskandarajah, Gavasker A., et al.
Publicado: (2012)

Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer
por: Na, Im II, et al.
Publicado: (2007)

Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE)
por: Ryu, Min‐Hee, et al.
Publicado: (2022)

Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis
por: Kim, Jwa Hoon, et al.
Publicado: (2018)

Lack of association between the VEGFA gene polymorphisms and preterm birth in Korean women
por: Shi, Yue, et al.
Publicado: (2023)

Understanding Disease Susceptibility through Population Genomics
por: Han, Seonggyun, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5uj838281hd8pqultitgd6fied